Table 2 |
|||
|
Prevalence of anti-SRCR and anti-SR-A IgG in patients and healthy controls |
|||
|
Anti-SRCR positive (%) |
Anti-SR-A positive (%) |
Double positive (%) |
|
|
|
|||
|
Healthy control (n = 85) |
0 |
0 |
0 |
|
SLE (n = 65) |
18.5* |
33.8* |
7.7† |
|
RA (n = 65) |
3.1§ |
13.8* |
0 |
|
pSS (n = 25) |
0 |
12.0* |
0 |
|
|
|||
|
* P < 0.001 as compared with healthy controls. †P = 0.014 as compared with healthy controls. § P = 0.186 as compared with healthy controls. pSS, primary Sjögren syndrome; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SR-A, scavenger receptor A; SRCR, scavenger receptor cysteine-rich. |
|||
|
Chen et al. Arthritis Research & Therapy 2011 13:R9 doi:10.1186/ar3230 |
|||
